- Home
- CRESY vs ARVN Comparison
CRESY vs ARVN Comparison
Compare CRESY & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRESY
- ARVN
- Stock Information
- Founded
- CRESY 1936
- ARVN 2015
- Country
- CRESY Argentina
- ARVN United States
- Employees
- CRESY N/A
- ARVN N/A
- Industry
- CRESY Real Estate
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CRESY Finance
- ARVN Health Care
- Exchange
- CRESY Nasdaq
- ARVN Nasdaq
- Market Cap
- CRESY 615.0M
- ARVN 676.2M
- IPO Year
- CRESY 1997
- ARVN 2018
- Fundamental
- Price
- CRESY $11.92
- ARVN $12.82
- Analyst Decision
- CRESY
- ARVN Buy
- Analyst Count
- CRESY 0
- ARVN 23
- Target Price
- CRESY N/A
- ARVN $17.80
- AVG Volume (30 Days)
- CRESY 290.3K
- ARVN 3.1M
- Earning Date
- CRESY 11-10-2025
- ARVN 11-05-2025
- Dividend Yield
- CRESY 4.92%
- ARVN N/A
- EPS Growth
- CRESY N/A
- ARVN N/A
- EPS
- CRESY 0.18
- ARVN N/A
- Revenue
- CRESY $702,652,598.00
- ARVN $312,300,000.00
- Revenue This Year
- CRESY N/A
- ARVN N/A
- Revenue Next Year
- CRESY N/A
- ARVN N/A
- P/E Ratio
- CRESY $6.42
- ARVN N/A
- Revenue Growth
- CRESY 31.80
- ARVN 93.86
- 52 Week Low
- CRESY $8.39
- ARVN $5.90
- 52 Week High
- CRESY $14.23
- ARVN $27.00
- Technical
- Relative Strength Index (RSI)
- CRESY 60.43
- ARVN 74.49
- Support Level
- CRESY $11.43
- ARVN $10.00
- Resistance Level
- CRESY $12.06
- ARVN $11.51
- Average True Range (ATR)
- CRESY 0.55
- ARVN 0.73
- MACD
- CRESY -0.05
- ARVN 0.16
- Stochastic Oscillator
- CRESY 44.84
- ARVN 71.92
About CRESY Cresud S.A.C.I.F. y A.
Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.